Vascular function in impaired glucose tolerance - effect of pioglitazone - Vascular function in IGT

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002084-49-GB

Enrollment

104

Registered

2006-09-18

Start date

2006-09-13

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired glucose tolerance

Interventions

Trade Name: Actos Product Name: Pioglitazone Pharmaceutical Form: Tablet INN or Proposed INN: Pioglitazone CAS Number: 111025-46-8

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects will have impaired glucose tolerance. They should be aged 18-70 years. Body mass index should be >25. They should be otherwise fit and well. They may have hypertension controlled =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Blood pressure >140/90 mmHg or requiring more than one anti-hypertensive agent to be controlled x2 normal). Women who are pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Main Objective: To study free radical (nitric oxide, superoxide), biochemical (glucose, lipids, HBA1c) and inflammatory (IL-6, adiponectin) markers and vascular function in patients with impaired glucose tolerance compared with healthy controls. ;Secondary Objective: We will monitor the effects of pioglitazone administered for 12 weeks on these markers.; Primary end point(s): Primary outcomes: Improved nitric oxide bioactivity, increased adiponectin levels and reduced IL-6 levels. Secondary outcomes: Improved vascular reactivity with pioglitazone.	—

Measure

Time frame

Main Objective: To study free radical (nitric oxide, superoxide), biochemical (glucose, lipids, HBA1c) and inflammatory (IL-6, adiponectin) markers and vascular function in patients with impaired glucose tolerance compared with healthy controls. ;Secondary Objective: We will monitor the effects of pioglitazone administered for 12 weeks on these markers.; Primary end point(s): Primary outcomes: Improved nitric oxide bioactivity, increased adiponectin levels and reduced IL-6 levels. Secondary outcomes: Improved vascular reactivity with pioglitazone.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026